Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

NCT00387374 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

Adenosquamous Cell Lung Cancer
Drug/Agent Toxicity by Tissue/Organ
Hemoptysis
Squamous Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: paclitaxel
DRUG: carboplatin
RADIATION: radiation therapy

Sponsor

National Cancer Institute (NCI)